-Dragonfly Therapeutics presentará datos preclínicos sobre DF6215 en etapa clínica, su agonista activo de IL-2R alfa diseñado, y DF9001, su TriNKET® dirigido al EGFR, en la Conferencia Anual de la Sociedad de Inmunoterapia del Cáncer (SITC) Actualmente, DF9001 se está evaluando para el…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.